Drilldown: Medicines
Medicines > classes 
:
Analgesic or
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]]
:
Analgesic or
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] Use the filters below to narrow your results.
generic:
Butorphanol (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Irbesartan (1) ·
Levorphanol (1) ·
Losartan (1) ·
Meperidine (1) ·
Nalbuphine (1) ·
Olmesartan (medoxomil) (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Tapentadol (1) ·
Telmisartan (1) ·
Valsartan (1)
brand:
None (5) ·
(multiple, generic dominant) (1) ·
Avapro (1) ·
Benicar (1) ·
Cozaar (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Diovan; Entresto (in fixed-dose combination with sacubitril) (1) ·
Duragesic (1) ·
Micardis (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Stadol (1) ·
Talwin (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
'"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) ·
'"`UNIQ--vote-000004C8-QINU`"' Largely hepatically cleared (~80% biliary); no active metabolite. Sacubitril-valsartan (Entresto) combines an ARB with neprilysin inhibition for HFrEF and was a notable advance over the ARB-alone trial (PARADIGM-HF, 2014)'"`UNIQ--ref-000004C9-QINU`"'. (1) ·
'"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1) ·
'"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1)
uses:
None (15) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"' (1) ·
'"`UNIQ--vote-000004CA-QINU`"', '"`UNIQ--vote-000004CB-QINU`"', '"`UNIQ--vote-000004CC-QINU`"' (1) ·
'"`UNIQ--vote-0000056B-QINU`"' (1) ·
'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1) ·
'"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1)
starting dose:
None (15) ·
150 mg PO once daily; titrate to 300 mg if needed (1) ·
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) ·
40 mg PO once daily; titrate to 80 mg (1) ·
50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) ·
80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID) (1) ·
Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
fda max:
onset:
duration:
halflife:
None (15) ·
11-15 hours'"`UNIQ--ref-00000842-QINU`"' (1) ·
2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) ·
2.5–3 hours (1) ·
~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) ·
~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-000004CD-QINU`"' (1)
bioavailability:
None (15) ·
42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) ·
60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) ·
~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"' (1) ·
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) ·
~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (15) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000004CF-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)
Showing below up to 21 results in range #1 to #21.